Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US

Tieu, H.-V., Karuna, S., Huang, Y., Sobieszczyk, M. E., Zheng, H., Tomaras, G. D., Montefiori, D. C., Shen, M., DeRosa, S., Cohen, K., Isaacs, M. B., Regenold, S., Heptinstall, J., Seaton, K. E., Sawant, S., Furch, B., Pensiero, M., Corey, L., & Bar, K. J. (2023). Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1–uninfected adult participants in the US. Vaccine, 41(42), 6309–6317. https://doi.org/10.1016/j.vaccine.2023.07.046
Authors:
Hong-Van Tieu
Shelly Karuna
Yunda Huang
Magdalena E Sobieszczyk
Hua Zheng
Georgia D Tomaras
David C Montefiori
Mingchao Shen
Stephen DeRosa
Kristen Cohen
Margaret Brewinski Isaacs
Stephanie Regenold
Jack Heptinstall
Kelly E Seaton
Sheetal Sawant
Brianna Furch
Michael Pensiero
Lawrence Corey
Katharine J Bar
Affiliated Authors:
Hong-Van Tieu
Magdalena E Sobieszczyk
Author Keywords:
hiv vaccine
hiv-1
nih
phase 1 clinical trial
subtype c gp145 env protein
trimeric envelope protein
Publication Type:
Article
Unique ID:
10.1016/j.vaccine.2023.07.046
PMID:
Journal:
Publication Date:
Data Source:
PubMed

Record Created: